Neurotrack

Neurotrack operates at the intersection of digital cognitive assessment, clinical diagnostics, and remote care. Its offering differs from conventional paper-based or clinician-administered screens through a three-minute, patient-guided digital assessment that uses eye-movement research captured through a standard camera. The company targets health systems, primary care, virtual care, and care-at-home programs, giving it a broader deployment model than solutions restricted to specialist clinics. Its FDA Class II status, reported clinical validation, 27 peer-reviewed papers, and 11 patents provide stronger clinical and regulatory signals than many general wellness or consumer brain-training applications. Neurotrack's competitive position is therefore best characterized as a clinically oriented digital screening platform rather than a broad consumer wellness product. The Midi Health partnership illustrates a differentiated use case in women's health, while the company's core opportunity remains earlier identification and longitudinal monitoring of cognitive impairment.

Neurotrack's growth trajectory shows a long development cycle followed by an emphasis on scalable clinical distribution. Founded in 2012, the company raised two seed rounds in 2013 totaling $2.09 million, followed by a $7.5 million Series A in 2016, a $2 million Series A in 2017, and a $13.7 million Series B in 2018. A $3.3 million grant in 2019 and a $21 million Series C later that year brought capital to approximately $49.59 million before the 2022 financing. The final disclosed round, a $10 million venture round announced on Nov 1, 2022, lifted total funding to $60.39 million. Product development has progressed from a digital cognitive test to a broader platform with health education, coaching, instant scoring, and EHR-oriented provider workflows. The 2024 Midi Health partnership marked an important market-expansion point by applying the assessment to menopause-related cognitive complaints.